Alloreaction increases or restores CD40, CD54, and/or HLA molecule expression in acute myelogenous leukemia blasts, through secretion of inflammatory cytokines: Dominant role for TNFβ, in concert with IFNγ

Leukemia

Volumn 20, Issue 11, 2006, Pages 1992-2001

  Eljaafari, A ^a,b   Van Snick, J ^c   Voisin, A ^a   Cormont, F ^c   Farre, A ^a   Bienvenu, J ^d   Bernaud, J ^a   Rigal, D ^a   Thomas, X ^b  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOIMMUNITY; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; BLOOD SMEAR; BONE MARROW; CELL INTERACTION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOCHEMISTRY; CYTOFLUOROMETRY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; LYMPHOCYTE DIFFERENTIATION; MALE; MIXED LEUKOCYTE CULTURE; MIXED LYMPHOCYTE REACTION; MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SUPERNATANT; T LYMPHOCYTE; UPREGULATION;

EID: 33750363285     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404375     Document Type: Article

References (30)

1. Butturini A, Bortin MM, Gale RP. The graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant 1987; 2: 233-242.
2. Cornelissen JJ, Lowenberg B. Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2005, 151-155.
3. Porter DL, Connors JM, Van Deerlin V, Duffy K, Mc Garigle C, Saidman SL et al. Graft-versus tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol 1999; 17: 1234-1243.
4. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006; 43: 3-10.
5. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83: 2360-2367.
6. Krenger W, Hill GR, Ferrara JL. Cytokine cascades in acute graft-versus-host disease. Transplantation 1997; 64: 553-558.
7. Allen RD, Staley TA, Sidman CL. Differential cytokine expression in acute and chronic murine graft-versus-host-disease. Eur J Immunol 1993; 23: 333-337.
8. Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 1999; 104: 459-467.
9. Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev 2003; 17: 187-194.
10. Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Ann Rev Med 2003; 54: 29-52.
11. Cooked RR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A et al. LPS antagonism reduces graft-versus-host-disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 107: 1581-1589.
12. Reddy P, Ferrara JL. Role of interleukin-18 in acute graft-vs-host disease. J Lab Clin Med 2003; 141: 365-371.
13. Wu CJ, Biernacki M, Kutok JL, Rogers S, Chen L, Yang XF et al. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res 2005; 11: 4504-4511.
14. Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukaemia. In marrow transplant patients. Blood 1990; 76: 2462-2465.
15. Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA, Barbui AM, van Egmond HM, Strijbosch MP et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia 2004; 18: 798-808.
16. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018-1023.
17. Choudhury A, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 1999; 93: 780-786.
18. Charbonnier A, Gaugler B, Sainty D, Lafage-Pochitaloff M, Olive D. Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. Eur J Immunol 1999; 29: 2567-2578.
19. Cignetti A, Bryant E, Allione B, Vitale A, Foa R, Cheever MA CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood 1999; 94: 2048-2055.
20. Kharfan-Dabaja M, Ayala E, Lindner I, Cejas PJ, Bablis NJ, Kolonias D et al. Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: Analysis of various differentiation-inducing signals. Cancer Immunol Immunother 2005; 54: 25-36.
21. Eljaafari A, Farre A, Duperrier K, Even J, Vie H, Michall et M et al. Generation of helper and cytotoxic CD4+T cell clones specific for the minor histocompatibility antigen H-Y, after in vitro priming of human T cells by HLA-identical monocyte-derived dendritic cells. Transplantation 2000; 71: 1449-1455.
22. Brouwer RE, van der Heiden P, Schreuder GM, Mulder A, Datema G, Anholt JD et al. Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be interferon. Hum Immunol 2002; 63: 200-210.
23. Gob CR, Porter AG. Structural and functional domains in human tumour necrosis factors. Protein Eng 1991; 4: 385-389.
24. Androlewicz MJ, Browning JL, Ware CF. Lymphotoxin is expressed as a heteromeric complex with a distinct 33-kDa glycoprotein on the surface of an activated human T cell hybridoma. J Biol Chem 1992; 267: 2542-2547.
25. Paul NC, Ruddle NH. Lymphotoxin. Annu Rev Immunol 1988; 6: 407-438.
26. Schuchmann M, Hess S, Bufler P, Brakebusch C, Wallach D, Porter A et al. Functional discrepancies between tumor necrosis factor and lymphotoxinαexplained by trimer stability and distinct receptor interactions. Eur J Immunol 1995; 25: 2183-2189.
27. Chaturvedi MM, LaPushin R, Aggarwal BB. Tumor necrosis factor and lymphotoxin. Qualitative and quantitative difference in the mediation of early and late cellular response. J Biol Chem 1994; 269: 14575-14583.
28. Holler E, Kolb HJ, Mittermuller J, Kaul M, Ledderose G, Duell T et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: Role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 1995; 86: 890-899.
29. Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant 2003; 9: 292-303.
30. Laurin D, Kanitakis J, Bienvenu J, Bardin C, Bernaud J, Lebecque S et al. Allogeneic reaction induces dendritic cell maturation through proinflammatory cytokine secretion. Transplantation 2004; 77: 267-275.